Latest & greatest articles for alzheimer's disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on alzheimer's disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on alzheimer's disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for alzheimer's disease

1. A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease

A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease UTCAT3403, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title A Significant Association Exists Between Periodontal Disease and Alzheimer’s Disease Clinical Question Is a patient with periodontal disease at higher risk of developing Alzheimer’s disease, compared to an individual without periodontal disease? Clinical Bottom Line (...) A significant association exists between periodontitis and Alzheimer’s disease, proposing that patients with periodontal disease are at higher risk of developing Alzheimer’s disease. This proposal is supported by a systematic review and robustly powered retrospective matched-cohort study. Based on the findings of these references, it can be postulated that patients with severe periodontitis who have been exposed to the disease for a minimum of 10 years are at greatest risk for developing Alzheimer’s disease

2019 UTHSCSA Dental School CAT Library

2. Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. (PubMed)

Mini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a secondary care setting. The diagnosis of Alzheimer's disease dementia and other dementias relies on clinical assessment. There is a high prevalence of cognitive disorders, including undiagnosed dementia in secondary care settings. Short cognitive tests can be helpful in identifying those who require further specialist diagnostic assessment; however, there is a lack of consensus around the optimal tools (...) to use in clinical practice. The Mini-Cog is a short cognitive test comprising three-item recall and a clock-drawing test that is used in secondary care settings.The primary objective was to determine the diagnostic accuracy of the Mini-Cog for detecting Alzheimer's disease dementia and other dementias in a secondary care setting. The secondary objectives were to investigate the heterogeneity of test accuracy in the included studies and potential sources of heterogeneity. These potential sources

Full Text available with Trip Pro

2019 Cochrane

3. ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors

ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors ADDENDUM: Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors Jill S. Goldman, MS, MPhil 1,2 , Susan E. Hahn, MS 3 , Jennifer Williamson Catania, MS, MPH 1,2 , Susan LaRusse-Eckert, MS 2 , Melissa (...) the following considerations in reaffirming this document: 1. To use the phrase “pathogenic variant” rather than the word “mutation” in discussing pathogenic variants related to autosomal dominant early-onset Alzheimer disease. This would be consistent with current ACMG/AMP Guidelines for Variant Interpretation and Reporting 1 . 2. Because this document no longer meets the criteria for an evidence-based practice guideline by either the American College of Medical Genetics and Genomics (ACMG) or National

2019 American College of Medical Genetics and Genomics

4. Effects of vitamin D supplementation on cognitive function and blood Abeta-related biomarkers in older adults with Alzheimer`s disease: a randomised, double-blind, placebo-controlled trial

Effects of vitamin D supplementation on cognitive function and blood Abeta-related biomarkers in older adults with Alzheimer`s disease: a randomised, double-blind, placebo-controlled trial Our study aimed to assess the effect of a 12-month vitamin D supplementation on cognitive function and amyloid beta (Aβ)-related biomarkers in subjects with Alzheimer's disease (AD). METHODS : This was a randomised, double-blind, placebo-controlled trial. 210 AD patients were randomly divided

2019 EvidenceUpdates

5. INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease

INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease To evaluate the safety and efficacy of low-dose naproxen for prevention of progression in presymptomatic Alzheimer disease (AD) among cognitively intact persons at risk.Investigation of Naproxen Treatment Effects in Pre-symptomatic Alzheimer's Disease (INTREPAD), a 2-year double-masked pharmaco-prevention trial, enrolled 195 AD family history-positive elderly (mean age 63 years) participants screened (...) carefully to exclude cognitive disorder (NCT-02702817). These were randomized 1:1 to naproxen sodium 220 mg twice daily or placebo. Multimodal imaging, neurosensory, cognitive, and (in ∼50%) CSF biomarker evaluations were performed at baseline, 3, 12, and 24 months. A modified intent-to-treat analysis considered 160 participants who remained on-treatment through their first follow-up examination. The primary outcome was rate of change in a multimodal composite presymptomatic Alzheimer Progression Score

2019 EvidenceUpdates

6. Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow

Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow Prescrire IN ENGLISH - Spotlight ''Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow'', 1 May 2019 {1} {1} {1} | | > > > Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |  (...)  |  Spotlight Drugs for Alzheimer's disease: reduction in the number of prescriptions is too slow A study conducted by the independent French medical journal Prescrire shows a reduction of only around 26% in the number of patients in France exposed to at least one Alzheimer's disease drug between 2012 and 2017. In approximately 3 out of 4 newly exposed patients, treatment lasted for more than 6 months, despite the proven harms. In France, as far back as 2011, the pharmacoeconomic committee

2019 Prescrire

7. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. (PubMed)

Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease. Prodromal Alzheimer's disease offers an opportunity to test the effect of drugs that modify the deposition of amyloid in the brain before the onset of dementia. Verubecestat is an orally administered β-site amyloid precursor protein-cleaving enzyme 1 (BACE-1) inhibitor that blocks production of amyloid-beta (Aβ). The drug did not prevent clinical progression in a trial involving patients with mild-to-moderate dementia due (...) of the trial regimen. The estimated mean change from baseline to week 104 in the CDR-SB score was 1.65 in the 12-mg group, 2.02 in the 40-mg group, and 1.58 in the placebo group (P = 0.67 for the comparison between the 12-mg group and the placebo group and P = 0.01 for the comparison between the 40-mg group and the placebo group), suggesting a worse outcome in the higher-dose group than in the placebo group. The estimated rate of progression to dementia due to Alzheimer's disease was 24.5, 25.5, and 19.3

Full Text available with Trip Pro

2019 NEJM Controlled trial quality: predicted high

8. Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. (PubMed)

Use of postmenopausal hormone therapy and risk of Alzheimer's disease in Finland: nationwide case-control study. To compare the use of hormone therapy between Finnish postmenopausal women with and without a diagnosis for Alzheimer's disease.Nationwide case-control study.Finnish national population and drug register, between 1999 and 2013.All postmenopausal women (n=84 739) in Finland who, between 1999 and 2013, received a diagnosis of Alzheimer's disease from a neurologist or geriatrician (...) , and who were identified from a national drug register. Control women without a diagnosis (n=84 739), matched by age and hospital district, were traced from the Finnish national population register.Data on hormone therapy use were obtained from the Finnish national drug reimbursement register.Odds ratios and 95% confidence intervals for Alzheimer's disease, calculated with conditional logistic regression analysis.In 83 688 (98.8%) women, a diagnosis for Alzheimer's disease was made at the age of 60

Full Text available with Trip Pro

2019 BMJ

9. Interventions to improve balance function in elderly with Alzheimer Disease: a systematic review

Interventions to improve balance function in elderly with Alzheimer Disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address (...) A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess the robustness of the findings of the meta-analysis, the analyses are re-run using the alternative

2019 PROSPERO

10. Addressing inclusion of disadvantaged populations in Alzheimer's disease research: a systematic review of recruitment and retention strategies and participant perspectives

Addressing inclusion of disadvantaged populations in Alzheimer's disease research: a systematic review of recruitment and retention strategies and participant perspectives Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (...) no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess

2019 PROSPERO

11. A systematic review of the clinical and economic outcomes associated with guideline-recommended food provision studies in heart disease, diabetes, chronic kidney disease, Alzheimer's disease, and older adults

A systematic review of the clinical and economic outcomes associated with guideline-recommended food provision studies in heart disease, diabetes, chronic kidney disease, Alzheimer's disease, and older adults Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc

2019 PROSPERO

12. A systematic review of instruments that assess the priorities, experiences, and perceptions of informal caregivers of persons with dementia or Alzheimer's disease

A systematic review of instruments that assess the priorities, experiences, and perceptions of informal caregivers of persons with dementia or Alzheimer's disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr (...) no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess

2019 PROSPERO

13. Spore powder of ganoderma lucidum for Alzheimer's disease: a systematic review

Spore powder of ganoderma lucidum for Alzheimer's disease: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect (...) A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess the robustness of the findings of the meta-analysis, the analyses are re-run using the alternative

2019 PROSPERO

14. The effect of cognitive intervention on cognitive function in older adults with Alzheimer's Disease: a systematic review and meta-analysis

The effect of cognitive intervention on cognitive function in older adults with Alzheimer's Disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne (...) studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess the robustness of the findings of the meta

2019 PROSPERO

15. Efficacy and safety of glycogen synthase kinase 3 inhibitors for Alzheimer's disease: a systematic review and meta-analysis

Efficacy and safety of glycogen synthase kinase 3 inhibitors for Alzheimer's disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence (...) is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how subgroup variables are stratified etc. In order to assess the robustness of the findings of the meta-analysis, the analyses

2019 PROSPERO

16. Amyloid-beta (Aß)-targeting immunotherapy for mild-to-moderate Alzheimer's disease: systematic review and meta-analysis

Amyloid-beta (Aß)-targeting immunotherapy for mild-to-moderate Alzheimer's disease: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO

17. Auditory electrophysiological assessments of alzheimer's disease and pre-clinical stages: a systematic review

Auditory electrophysiological assessments of alzheimer's disease and pre-clinical stages: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO

18. Genetic associations in Alzheimer's Disease: a systematic review and meta-analysis

Genetic associations in Alzheimer's Disease: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email (...) of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome, the choice of effect measure, how

2019 PROSPERO

19. Identifying the role of hypertension in the neuropathology of Alzheimer's disease a systematic review and meta-analysis

Identifying the role of hypertension in the neuropathology of Alzheimer's disease a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO

20. Systematic review and meta-analysis of associations between subjective cognitive decline and biomarkers of Alzheimer's disease

Systematic review and meta-analysis of associations between subjective cognitive decline and biomarkers of Alzheimer's disease Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any (...) cell dose (linear); blinding of outcome assessment reported (stratified yes vs no). For stratified analyses, a minimum number of 8 studies per subgroup is required. ">Subgroup analyses A sensitivity analysis is conducted to assess the impact of decisions taken in the review process on the meta-analysis outcome. These decisions may have been made in various stages of the review, e.g. the decision to exclude certain disease models, the decision to pool certain units of measurement for an outcome

2019 PROSPERO